Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder.

OBJECTIVES Photodynamic diagnosis (PDD) using 5-aminolevulinic acid has proved to be a procedure with an outstanding sensitivity for the detection of transitional cell carcinoma of the bladder, in particular in the detection of flat urothelial lesions. We report on our clinical results with 875 patients (1713 PDD procedures) between March 1995 and March 2002. METHODS A total of 1713 PDD procedures were done in 875 patients. Fluorescence imaging was performed 2 to 3 hours after instillation of 50 mL of a 3% solution of 5-aminolevulinic acid into the bladder by an incoherent light source. In total, specimens from 4630 lesions (2.7 lesions/PDD) were taken. RESULTS In 34.8% of all biopsies, the histologic finding was malignant; 23.7% of these biopsies had been taken only because of positive fluorescence. In 28.5% of the positive biopsies, flat lesions had been identified. Also, 43.4% of carcinoma in situ and 30.7% of dysplasia II degrees were detected only by positive fluorescence. Of all tumor lesions, 92.0% were detected by PDD compared with 76.3% detected by white light endoscopy. CONCLUSIONS PDD has proved to be an effective detection device for superficial bladder cancer.

[1]  Herbert Stepp,et al.  Role of 5‐aminolevulinic acid in the detection of urothelial premalignant lesions , 2002, Cancer.

[2]  Gerhard Jakse,et al.  A second-look TUR in T1 transitional cell carcinoma: why? , 2004, European urology.

[3]  A. Althausen,et al.  Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. , 1976, The Journal of urology.

[4]  R. Knuechel,et al.  Clinical Results of the Transurethral Resection and Evaluation of Superficial Bladder Carcinomas by Means of Fluorescence Diagnosis after Intravesical Instillation of 5-Aminolevulinic Acid , 1999 .

[5]  G. Steineck,et al.  Prevention and Treatment of Urothelial Premalignant and Malignant Lesions , 2000, Scandinavian journal of urology and nephrology. Supplementum.

[6]  J. Cheville,et al.  Flat intraepithelial lesions of the urinary bladder , 2000, Cancer.

[7]  L. Guillou,et al.  Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light‐induced fluorescence of protoporphyrin IX following topical application of 5‐aminolevulinic acid: Preliminary results , 1997, Lasers in surgery and medicine.

[8]  K. Schomacker,et al.  Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5‐aminolaevulinic acid , 1999, BJU international.

[9]  L. Kiemeney,et al.  Random bladder biopsies and the risk of recurrent superficial bladder cancer: a prospective study in 1026 patients , 1992, World Journal of Urology.

[10]  R. Knuechel,et al.  Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses , 2003, The Journal of pathology.

[11]  G. Steineck,et al.  Epidemiology and Etiology of Premalignant and Malignant Urothelial Changes , 2000, Scandinavian journal of urology and nephrology. Supplementum.

[12]  Thomas Filbeck,et al.  Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. , 2002, The Journal of urology.

[13]  C. De Nunzio,et al.  Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity. , 2001, Urology.

[14]  M. Soloway,et al.  Serial multiple-site biopsies in patients with bladder cancer. , 1978, The Journal of urology.

[15]  R. Knuechel,et al.  Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. , 2002, Cancer research.

[16]  H Stepp,et al.  Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. , 1996, The Journal of urology.

[17]  S. Wilczynski,et al.  The accuracy of urinary cytology in daily practice , 1999, Cancer.

[18]  J. Rassweiler,et al.  Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. , 2002, The Journal of urology.

[19]  D. Zaak,et al.  The Current Diagnosis of Superficial Bladder Cancer Must Be Reconsidered , 2002, Urologia Internationalis.

[20]  F M Debruyne,et al.  Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. , 1994, European journal of cancer.

[21]  W Roessler,et al.  5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. , 1999, Urology.

[22]  R. Sylvester,et al.  Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative Group , 1999, European Urology.

[23]  P Schneede,et al.  Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. , 2001, Urology.

[24]  J. Witjes.  Bladder carcinoma in situ in 2003: state of the art. , 2004, European urology.

[25]  R. Knuechel,et al.  [Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study]. , 2003, Der Urologe. Ausg. A.

[26]  A Hofstetter,et al.  Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. , 1999, The American journal of pathology.

[27]  J. Cheville,et al.  Natural history of urothelial dysplasia of the bladder. , 1999, The American journal of surgical pathology.

[28]  H. Huland,et al.  Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. , 1991, The Journal of urology.

[29]  C. Busch,et al.  Recurrence and progression in low grade papillary urothelial tumors. , 1999, The Journal of urology.